David R. Langley

E-Novo: An Automated Workflow for Efficient Structure-Based Lead Optimization

Hongwei Huang, Jia Kang, Amit Kulkarni, 2009, J. Chem. Inf. Model..

MORPH: A New Tool for Ligand Design

David R. Langley, Brett R. Beno, B. Beno, 2010, J. Chem. Inf. Model..

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Nicholas A. Meanwell, Lawrence G. Hamann, 2010, Nature.

X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir

Steven Sheriff, Kevin Kish, Ronald E. Rose, 2007, Journal of Virology.

Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors

Michael L. Doyle, Ronald E. Rose, David R. Langley, 2005, Antimicrobial Agents and Chemotherapy.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

Min Gao, Nicholas A. Meanwell, Yong Tu, 2015, Nature.

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Ronald E. Rose, David R. Langley, D. Langley, 2007, Journal of Virology.